首页> 外文期刊>Obstetrics and Gynecology: Journal of the American College of Obstetricians and Gynecologists >A protocol of dual prophylaxis for venous thromboembolism prevention in gynecologic cancer patients.
【24h】

A protocol of dual prophylaxis for venous thromboembolism prevention in gynecologic cancer patients.

机译:在妇科癌症患者中预防静脉血栓栓塞的双重预防方案。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

OBJECTIVE: To evaluate a quality improvement protocol for venous thromboembolism prevention in postoperative gynecologic cancer patients. METHODS: On January 1, 2006, we initiated a universal protocol of dual prophylaxis with sequential compression devices and three times daily heparin (or daily low molecular weight heparin) until discharge in gynecologic cancer patients having major surgery. Patients with both malignancy and age over 60 years (or history of prior clot) were discharged on 2 weeks of anticoagulant. Before January 2006, all patients were given sequential compression devices starting before the induction of anesthesia, continuing until discharge from the hospital. Records of gynecologic cancer service patients admitted in 2005 and 2006 were reviewed, excluding patients with a history of heparin-induced thrombocytopenia or those admitted on an anticoagulant. Any pulmonary embolism or deep vein thrombosis diagnosed within 6 weeks of surgery was identified. We performed chi2 and Wilcoxon rank sum tests as well as multivariable regression analysis for confounders. RESULTS: Six of the 311 women meeting inclusion criteria in 2006 (1.9%) and 19 of 294 (6.5%) in 2005 had venous thromboembolism (odds ratio 0.33, 95% confidence interval 0.12-0.88, multivariable analysis adjusting for baseline differences between the groups). Heparin was given to 98.1% of patients in the hospital in 2006, and 91.1% of those meeting high-risk criteria were discharged on an anticoagulant. No differences in major bleeding complications were seen between years. CONCLUSION: A protocol of dual prophylaxis with prolonged prophylaxis in high-risk patients was successfully implemented and was associated with a significant reduction in the rate of venous thromboembolism without increasing bleeding complications. LEVEL OF EVIDENCE: II.
机译:目的:评估术后妇科恶性肿瘤患者静脉血栓栓塞预防的质量改进方案。方法:2006年1月1日,我们启动了采用顺序加压装置和每日三次肝素(或每日低分子量肝素)两次预防的通用预防方案,直到妇科癌症大手术患者出院。患有恶性肿瘤且年龄超过60岁(或既往有凝块史)的患者均在2周的抗凝治疗后出院。在2006年1月之前,所有患者在麻醉开始前均先后接受连续加压装置,一直持续到出院为止。回顾了2005年和2006年收治的妇科癌症服务患者的记录,不包括有肝素诱发的血小板减少病史或接受抗凝剂治疗的患者。确认在手术后6周内诊断出的任何肺栓塞或深静脉血栓形成。我们对混杂因素进行了chi2和Wilcoxon秩和检验以及多元回归分析。结果:2006年达到入选标准的311名女性中有6名(1.9%),2005年达到294名中的19名(6.5%)患有静脉血栓栓塞(赔率0.33,95%的置信区间0.12-0.88,多变量分析调整了两组之间的基线差异)。组)。 2006年,医院为98.1%的患者提供了肝素,符合高危标准的患者中有91.1%的患者使用了抗凝剂。几年之间在主要出血并发症方面没有差异。结论:成功实施了高危患者双重预防和长期预防的协议,该协议可显着降低静脉血栓栓塞发生率,而不会增加出血并发症。证据级别:II。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号